Clinical Trials Logo

Epithelial Ovarian Cancer clinical trials

View clinical trials related to Epithelial Ovarian Cancer.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT03393884 Active, not recruiting - Clinical trials for Fallopian Tube Cancer

Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)

OVATION 2
Start date: September 5, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus NACT compared to NACT alone.

NCT ID: NCT03371693 Active, not recruiting - Ovarian Cancer Clinical Trials

Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer

HIPECOV
Start date: September 30, 2017
Phase: Phase 3
Study type: Interventional

A phase III prospective study with the primary objective to compare the efficacy and safety of HIPEC( Hyperthermic Intraperitoneal Chemotherapy). The target population for this study is patients with primary or recurrence ovarian, peritoneal or fallopian tube cancers undergoing CRS( Cytoreductive Surgery). Patients will be divided into two groups. Group A will undergo CRS plus HIPEC and then go on to receive standard platinum-based combination doublet intravenous chemotherapy. Group B will undergo CRS and then go on to intravenous chemotherapy.

NCT ID: NCT02644369 Active, not recruiting - Clinical trials for Advanced Solid Tumors

Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors

INSPIRE
Start date: March 21, 2016
Phase: Phase 2
Study type: Interventional

This is a phase 2 study whose main purpose is to evaluate gene changes and immune biomarkers in patients with solid tumors during treatment with pembrolizumab and in relation to response to treatment. Pembrolizumab is a monoclonal antibody that is designed to block a protein called programmed cell death 1 ligand 1 (PD-L1) which will allow the body's immune system to kill the cancer cells.

NCT ID: NCT02124421 Active, not recruiting - Clinical trials for Fallopian Tube Cancer

HOT: HIPEC in Ovarian Cancer as Initial Treatment

CRS/HIPEC
Start date: April 2014
Phase: Phase 2
Study type: Interventional

Community hospital based phase II (prospective randomized) study to evaluate the toxicity of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in newly diagnosed, otherwise untreated, advanced stage (stage III/IV) epithelial ovarian, fallopian tube, and primary peritoneal cancer.

NCT ID: NCT01447706 Active, not recruiting - Clinical trials for Fallopian Tube Cancer

A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers

Start date: October 2011
Phase: Phase 2
Study type: Interventional

To determine whether the combination of MM-121 plus paclitaxel is more effective than paclitaxel alone

NCT ID: NCT01276574 Active, not recruiting - Clinical trials for Fallopian Tube Cancer

Epithelial Ovarian Cancer- Staging and Response to Chemotherapy Evaluated by PET/CT

Mupet
Start date: October 2009
Phase:
Study type: Observational

The purpose of this study is to determine, whether there is clinical benefit of using fdg-PET/CT (F-18-fluorodeoxyglucose- positron emission tomography/computed tomography)compared to contrast-enhanced CT in primary treatment of advanced epithelial ovarian cancer (EOC) - Objectives - the impact of preoperative PET/CT compared to CT on EOC stage definition - to compare the value of preoperative PET/CT, CT and laparoscopy in intra-abdominal tumour assessment. Laparotomy findings evaluated by surgeon and histopathologic results serve as the reference standard. - to compare serum markers HE4(human epididymis protein 4) and CA125 (cancer antigen 125) with FDG-PET/CT and CT in treatment response evaluation during neoadjuvant chemotherapy and primary treatment of EOC - to compare FDG PET/CT based treatment response evaluation with RECIST and GCIG criteria - Methods - All the patients will undergo FDG-PET/CT prior surgery, after possible neoadjuvant chemotherapy (NACT) and 4 weeks after completion of primary platinum-based chemotherapy. - CA125 and HE4 levels are measured pre-operatively, with every chemotherapy cycle and regularly during follow-up until 1st disease relapse